since it is recognized that reactive AGEs can readily be derived from the modern diet (9, 17, 18, 32, 39) . Thus, whereas it has long been known that AGEs may promote chronic cell injury and elevated OS in disease states, it is now increasingly apparent that they accumulate and induce pathological changes before the onset of recognizable diseases (9, 38) .
Intracellular oxidant status is influenced by unopposed or excess reactive oxygen species (ROS) in the cytosol or mitochondria (27) . Increased cellular ROS can also arise from AGEs in the absence of elevated glucose; e.g., from myeloperoxidase and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase or from lipids (3, 4, 17) . ROS may be increased via activation of AGE-sensitive cell surface receptors, such as receptor for advanced glycation end products (RAGE) (5, 33) , or nonreceptor-dependent pathways, causing activation of mitogen-activated protein kinase (MAPK)/Ras and nuclear factor (NF)-B, as well as of Akt, forkhead transcription factors (FOXO), p38, or c-JUN pathways, which can promote both inflammatory responses or cellular apoptosis (2, 24) .
Certain cell surface receptors, such as RAGE, promote AGE-induced OS and inflammatory responses (5, 33) , whereas a second category, which includes AGER1, reduces AGE levels and suppresses OS, RAGE, and inflammation (20, 22) . Since the balance between the responses mediated by these two types of receptors may determine cell fate, a clear understanding of the signaling pathways involved becomes critical. AGER1, an integral membrane protein localized in the endoplasmic reticulum (ER) and on plasma membranes, is associated with AGE endocytosis and removal (20, 22) . Overexpression of AGER1 in glomerular mesangial cells or human embryonic kidney 293 (HEK293) cells opposes AGE-mediated RAGE, MAPK, and NF-B-dependent inflammatory responses via inhibition of epidermal growth factor (EGFR) and the EGFR-dependent Tyr phosphorylation of Grb2 and Shc adaptor proteins p52 and p46, which directly transport signals to Ras (10, 20, 22) . The third Shc isoform p66 shc may be an essential regulator of mitochondrial and cytoplasmic OS and apoptosis, since p66 shc mutant mice are resistant to OS and have an extended lifespan (23, 25) . p66 shc functionally interacts with FKHRL1, a homologue of the forkhead family members that tightly regulates the transcription of anti-oxidant genes; e.g., MnSOD and catalase (19, 26) . MnSOD in particular is encoded by a nuclear gene, SOD2, which is tightly regulated by ROS via FKHRL1; however, this anti-oxidant pathway can be blocked by a mechanism regulated by p66
shc (19, 23, 26) . Oxidants, such as H 2 O 2 , ultraviolet light irradiation, or glucose induce phosphorylation of p66
Sch at CH 2 -Ser-36 residue, promoting ROS generation and the recruitment and activation of Akt/PKB (19, 23, 26, 34) . Activation of Akt/PKB by p66
Sch leads to phosphorylation of FKHRL1, keeping this inactive form in the cytosol (6) , and this has been proposed as a mechanism by which sustained OS compromises MnSOD availability and increases the sensitivity of cells to injury and apoptosis. Deletion of p66 shc largely blocks FKHRL1 phosphorylation and inactivation, leading to enhanced expression of MnSOD and to greater resistance to OS (6, 19, 23, 25, 26, 34) . Recent studies reveal an association among AGEs, OS, and p66 shc (9, 12, 16, 21) . Erk, a kinase previously linked to MAPK and NF-B activation by AGEs (10, 20, 22, 33) , was recently reported as a mediator of p66 shc Ser-36 phosphorylation (16) , and this interplay may modulate responses to aging and OS.
The present studies were undertaken to explore the effects of well-characterized AGEs on these interactions and to determine whether they are modulated by AGER1. The data suggest that specific AGEs can promote ROS-dependent Ser-36 phosphorylation of p66
shc , resulting in inactivation of FKHRL1 and suppression of MnSOD in HEK293 cells. This pathway can be blocked by AGER1 overexpression, identifying a novel mechanism by which AGER1 promotes anti-oxidant homeostasis.
MATERIALS AND METHODS
Materials. Phospho-Thr-32 FKHRL1 antibody was from Upstate Biotechnology (Lake Placid, NY), anti-Shc antibody from BD Biosciences (Transduction Laboratories), EGFR inhibitor AG 1478 from Calbiochem (La Jolla, CA), MEK inhibitor U0126 and anti-phospho-ERK antibody from Cell Signaling (Beverly, MA), anti-MnSOD antibody from Stressgen Biotechnologies (Victoria, BC, Canada), dihydroethidium from Molecular Probes (Eugene, OR), and phosphodetect anti-Shc/p66 shc (pSer 36 ) antibody from Calbiochem. The vectors expressing wild-type p66 shc (p66 Wt ) or expressing position-36 mutant (serine to alanine) of p66 shc (p66 SA ) were a generous gift from Dr. Toren Finkel (NHLBI, NIH, Bethesda, MD). Endotoxin-free BSA was used to prepare two chemically distinct AGEs: methylglyoxal (MG)-BSA, containing 22 MG-modified arginine residues per molecule, and CML-BSA, containing 23 CML-modified lysine residues per molecule, characterized by HPLC and GC-MS, as described (10, 11) . Endotoxin contaminants were removed by using an endotoxinbinding affinity column (Pierce, Rockford, IL), and final products contained Ͻ0.1 U/ml, as tested by a Limulus amoebocyte lysate assay (BioWhittaker, Walkersville, MD) (10, 11, 20, 22) .
Cell culture. HEK293 cells (ATCC CRL-1573) were maintained in MEM (supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS) at 37°C in 5% CO2. Before treatment, cells were washed in PBS 1ϫ and incubated with serumfree media for 12 h. Established stable HEK293 cell lines overexpressing human AGE-R1 (AGER1) were also used (10, 22) .
Western blot analysis. Cells were exposed to ligands at 37°C, rinsed (2ϫ in ice-cold PBS), and lysed in 500 l lysis buffer (New England Biolabs). After brief sonication, equal amounts of cell protein were separated on 10% or 8% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes, which were treated with the appropriate primary and secondary antibodies. Immunoreactive proteins were visualized using an enhanced chemiluminescence system (Roche). For reprobing, blots were stripped with buffer (50 mM of Tris ⅐ HCl, pH 6.8, 2% SDS, and 0.1 M ␤-mercaptoethanol), before the addition of a new primary antibody (10 shc (p66 SA ), using lipofectamine plus reagent (GIBCO-BRL), and 48 h later cells were exposed to CML-BSA, MG-BSA, or BSA before harvesting for Western blot analysis (10, 22, 26) .
Intracellular ROS. Intracellular superoxide anion levels were detected using dihydroethidium (HE) (35) . Briefly, cells were stimulated at the indicated AGE concentrations (100 g/ml CML-BSA, or 40 g/ml MG-BSA, 100 g/ml BSA) at 37°C for up to 4 h, washed with PBS, and incubated with HE (10 M) for another 45 min, and fluorescence was measured in the cellular extract with a fluorometer (extinction and emission wavelengths were 501 and 521 nm, respectively).
AGER1 siRNA. Quiescent HEK293 cells were transfected with AGER1 small interfering RNA (siRNA) using Lipofectin reagent (GIBCO-BRL), as previously described (10) . After 48 h cells were treated with CML-BSA for another 24 h, and the lysates were analyzed for MnSOD expression by Western blot analysis.
RESULTS

AGEs induce Ser-36 phosphorylation of p66
sh and FKHRL1 phosphorylation, both events are suppressed in HEK293 cells overexpressing AGER1. We previously observed that AGEs promote rapid Tyr phosphorylation of p46 and p52 shc , but not of p66
shc in mesangial and HEK293 cells, both of which express p66
shc (10) . HEK293 cells stimulated with CML-BSA (100 g/ml) showed rapid serine phosphorylation of p66 shc , which peaked by 5-15 min (Fig. 1A) . Similarly treated cells overexpressing AGER1 showed no changes in phospho-p66 shc levels from baseline values (Fig. 1A) . The MEK-Erk cascade is involved in p66
Shc Ser-36 phosphorylation, with (28) or without EGFR transactivation (16) , and AGEs promote Erk signaling through the transactivation of EGFR in HEK293 cells, a response that is blocked in cells overexpressing AGER1 (10) . To determine whether AGE-induced serine phosphorylation of p66 shc was a downstream target of the EGFR-MEK-Erk pathway, HEK293 cells were stimulated with AGEs or EGF in the presence or absence of the EGFR kinase inhibitor AG1478 and the MEK inhibitor U0126 (Fig. 1 , B and C). Since AGEs are heterogeneous, CML-BSA (13, 17, 32, 38) and a structurally distinct, but equally common AGE, MG-BSA (13, 17, 18, 39) were studied. Stimulation with these two types of AGEmodified BSA or EGF failed to promote Ser phosphorylation of p66 shc in the presence of EGFR or MEKK activation inhibitors (Fig. 1, B and C) . These data suggest that AGEs promote p66
Shc Ser phosphorylation via the EGFR-MAPK-Erk pathway (16) . Also, AGER1 inhibition of this pathway occurred most likely via an interaction with EGFR (10). Furthermore, AGEs promoted p66
Shc protein expression, persisting for at least 24 h, an effect not evident in AGER1 cells (Fig. 1D) . SA , indicating that these events were largely due to p66 Shc Ser-36 phosphorylation (Fig. 2, B and C) . Furthermore, AGE-induced FKHRL1 phosphorylation was blocked in cells overexpressing AGER1 cotransfected with either p66 WT or p66 V (Fig. 2, D and E) . Thus AGER1 inhibited AGE-induced p66
Shc Ser-36 phosphorylation, a key step leading to phosphorylation of FKHRL1. Akt is upstream from FKHRL1 (6, 34) and AGE stimulation induced Akt phosphorylation in a time-dependent manner from 5 to 20 min (Fig. 3A) . This time course mirrored the AGE-stimulated phosphorylation of FKHRL1, which also peaked between 5 and 20 min and decreased at 30 min (Fig. 3B ). An antioxidant (N-acetylcysteine, NAC), added to determine whether FHKRL1 phosphorylation was due to AGE-induced ROS, blocked the response induced by either CML-BSA or MG-BSA (Fig. 3C ). Whereas FHKRL1 phosphorylation by AGEs was dose dependent in HEK293 cells transfected with an empty vector, AGER1 cells were unresponsive to AGE levels, up to 200 g/ml (Fig. 3D) , and p66 SA cells were exposed to CML-BSA (100 g/ml), MG-BSA (40 g/ml), or BSA (100 g/ml) for 10 min. EGF was used as a positive control. Blots were probed with an anti-phospho-(Ser-36) p66 shc or anti-p66
shc . Densitometric data from 3 independent experiments is shown as the means Ϯ SD ratio of p66 WT . D and E: AGER1 cells were treated with CML-BSA (100 g/ml) for 10 min, respectively. Blots were probed with antibodies to phospho-Thr-32 FKHRL1 or total FKHRL1. Densitometric data from 3 independent experiments is shown as the ratio of p66
WT or p66 SA to p66 V . shc phosphorylation after stimulation with CML-BSA (100 g/ml), methyl glyoxal (MG, 40 g/ml), or EGF (100 ng/ml) in the presence or absence of AG1478 or U0126. Blots were probed with antibodies to phospho-Ser-36 of p66 shc or total p66 shc . C: Erk and phosphorylated Erk in cells were exposed to CML-BSA (100 g/ml), MG-BSA (40 g/ml), or EGF (100 ng/ml) in the presence or absence of AG1478 or U0126. Blots were probed with antibodies to phospho-ERK or total ERK. D: p66 shc protein expression after long exposure to CML-BSA (100 g/ml) (for 24 h) in AGER1 cells or HEK293-V cells. *P Ͻ 0.01 AGER1 vs. p66
V . Representative blots from 3 independent experiments are shown.
AGE-induced FKHRL1 phosphorylation is associated with reduced expression of MnSOD in HEK293 cells but not in AGER1 overexpressing cells.
We tested the effects of CML-BSA, MG-BSA, or native BSA on MnSOD levels, since FKHRL1 regulates its expression (19, 25) . Both AGEs led to significant suppression of MnSOD expression within 4 h (CML by 70% and MG by 50%, respectively) (Fig. 4, A and B) , which was sustained for 24 h by CML (Fig. 4B) . MnSOD suppression was nearly completely prevented by 5 mM NAC and partially (ϳ50%) by a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY-294002). Thus the suppression of MnSOD levels by CML-BSA and MG-BSA involves ROS and the PI3K pathway. Fig. 3 . AGE-induced reactive oxygen species (ROS) production mediates FKHRL1 phosphorylation via Akt in HEK293 cells and is blocked in AGER1 cells. A: Akt phosphorylation following treatment of cells with CML-BSA (100 g/ml) for 0 -30 min (as in Fig. 1 ). Blots were probed with antibodies to phospho-Akt and total-Akt. FKHRL1 phosphorylation is increased in cells after exposure to CML-BSA (100 g/ml) for 0 -30 min (B) and is inhibited by NAC (5 mM, for 15 min) (C). Blots were probed with antibodies to phospho-Thr-32 FKHRL1 or total FKHRL1. D: FKHRL1 phosphorylation was blocked in AGER1 cells, but not in HEK293 cells, after exposure to CML-BSA (0 -200 g/ml) for 15 min. Representative blots (top and middle) and densitometric data from 3 independent experiments (bottom) are shown as the ratio (means Ϯ SD) to unstimulated controls (*P Ͻ 0.01, **P Ͻ 0.001) or to stimulated HEK293 cells (#P Ͻ 0.01).
Fig. 4. AGEs suppress MnSOD protein expression in HEK293 cells.
A: cells were exposed to CML-BSA (100 g/ml), MG-BSA (40 g/ml), or BSA (100 g/ml) for up to 4 h. B: blots were probed with antibodies to MnSOD and ␤-tubulin. Representative blots (top) and densitometric data of 3 independent experiments (bottom) are expressed as the percentage of controls (CL). **P Ͻ 0.01 vs. 1 h. B: cells, pretreated with LY-294002 (25 M and 50 nM) or N-acetylcysteine (NAC, 1 mM and 5 mM), or buffer for 1 h were exposed to CML-BSA (100 g/ml) for 24 h. Blots were probed with antibodies to MnSOD and ␤-tubulin. Representative blot (top) and densitometric data from 3 independent experiments are shown as fold increase above control (bottom). *P Ͻ 0.01 vs. CML without inhibitors.
The dose-dependent inhibitory effect of CML-BSA on MnSOD seen in HEK293-V cells was significantly attenuated in AGER1 cells (Fig. 5, A and B) . This finding was AGER1 specific, since reducing AGER1 levels by siRNA transfection resulted in reappearance of CML-induced MnSOD inhibition. Therefore, the AGER1 actions include the regulation of MnSOD levels.
AGER1 blocks the RAGE-induced reduction in the expression of MnSOD by AGEs. Baseline levels of AGER1 production in HEK293 cells were reduced by transduction with AGER1 siRNA and increased by AGER1 (Fig. 6A) . Both CML and MG reduced MnSOD levels (Fig. 6B) . The levels of MnSOD were further decreased in cells transduced with RAGE. However, the levels of MnSOD remained unchanged in cells cotransfected with both AGER1 and RAGE. Thus CML and MG reduce MnSOD levels, and the levels are further decreased by the overexpression of RAGE. However, AGER1 blocks the RAGE-induced reduction of MnSOD expression. This is the first time that this action of AGER1 has been shown.
AGER1 overexpression suppresses the AGE-mediated cellular ROS generation associated with p66
shc activation. CML-BSA or MG-BSA stimulation resulted in significant increases in superoxide levels in p66 V cells (ϳ60% greater than control) and in p66 WT HEK293 cells (ϳ175% greater than control) (Fig. 7A) . In addition, the AGE-mediated ROS production was absent in AGER1 cells transiently cotransfected with p66 V and significantly attenuated in AGER1 cells transiently cotransfected with p66 WT (Fig. 7B ). Superoxide production in AGER1 cells by either AGE stimulant was significantly lower in p66 SA than in p66 WT transfectants, whether or not they coexpressed AGER1 (Fig. 7, A and B) . Thus Ser-36 phosphorylation of p66 shc is important for AGE-promoted ROS production and FKHRL1 phosphorylation. Since p66 shc phosphorylation was blocked in cells overexpressing AGER1, the expression levels of AGER1 may be key in its inhibition of ROS after AGE stimulation.
DISCUSSION
We found that AGEs promote p66
Shc Ser-36 phosphorylation and FKHRL1 transcription factor inactivation in a ROSdependent manner. AGE-induced ROS mediate early changes in the p66
Shc signaling pathway and also causes prolonged suppression of MnSOD. These data implicate p66
Shc in AGEinduced oxidant damage and cell injury via EGFR, MEKK, and Erk. Since cells that over express AGER1 are resistant to both AGE-induced oxidant damage and cell injury, the data also implicate AGER1 in the control of inflammatory signals, via MAPK-NF-B and also in the downregulation of transcriptional stress-response systems, via p66 Shc . Thus AGER1 may represent an important factor in cellular defenses against AGE or oxidant injury.
ROS, such as H 2 O 2 , O 2 Ϫ , and hydroxyl radicals, generated from AGEs have been implicated in aging and related disorders; i.e., diabetes, cardiovascular and kidney disease, and Alzheimer's disease (9, 13, 17, 18, 33, 39) . We recently found that two Shc isoforms (p52 shc and p46 shc ) but not p66 shc , undergo Tyr phosphorylation in response to AGEs via EGFR (10) . These data link AGEs to MAPK activation and proinflammatory responses via tyrosine kinase receptors. Others found that p66
shc plays a crucial role in the regulation of oxidative stress responses (23, 26) . We now show that AGEs also lead to p66
Shc Ser-36 phosphorylation in HEK293 cells overexpressing wild-type p66 shc but not in cells transfected with a dominant-negative Ser-36 mutant p66 shc p66 SA . Since FKHRL1 phosphorylation, induced by either CML-BSA or MG-BSA, was blocked in cells overexpressing p66 SA , p66
Shc may functionally interact with FKHRL1 under conditions of high levels of at least two common in vivo AGE prototypes CML and MG (8, 9, 11, 13, 17, 18, 32, 38, 39) . The Ser-36 phosphorylation of p66 shc is thought to serve in the generation of ROS for the recruitment and activation of Akt/PKB and the phosphorylation and inactivation of FKHRL1 (6, 26, 36 (23, 25) . We have found that aging mice exposed to a diet with a reduced oxidant burden had lower levels of p66
Shc protein, associated with reduced AGEs, lipid peroxides (8-isoprostanes), and RAGE, as well as a marked reduction of kidney disease (9) . This low OS state was linked to preservation of normal AGER1 levels, suggesting that this receptor could be functionally linked to low OS and p66 Shc protein (9) . Herein, AGE stimulation of HEK293 cells resulted in increased p66
Shc protein expression between 30 min and 24 h. Thus AGEs may promote sustained increase of cytosolic and mitochondrial p66
Shc levels (23, 25, 28) , and this might account for the elevated levels of p66
Shc protein seen in high-AGE states such as diabetes and aging (9, 30, 31, 39) .
Enhanced ROS levels in diabetes and aging are associated with sustained mitochondrial ROS overproduction or cytosolic NADPH oxidase activation (3, 8, 17, 24, 27) , both of which are linked to p66
Shc (16, 28, 29) . The Akt/PKB and FKHRL1 system is important in the pro-oxidant stress responses of p66
Shc (6, 14, 19, 26, 28, 30) . Specific activation of FKHRL1, a transcriptional regulator of key antioxidant enzymes, i.e., MnSOD, protects against cellular oxidants (19, 25) . Herein, exposure to AGEs led to a time-and dose-dependent phosphorylation of Akt and FKHRL1, responses that were suppressed by AGER1 overexpression. CML-BSA and MG-BSA markedly enhanced FKHRL1 phosphorylation in cells overexpressing wild-type p66
Shc , consistent with FKHRL1 inactivation (6, 34) . On the other hand, stable expression of the dominant negative interfering p66 SA restored normal FKHRL1 activity and rendered these mutant cells resistant to AGEinduced OS. These data suggest that in the setting of high AGEs, p66
Shc serine phosphorylation can contribute to excess OS via FKHRL1 inactivation. This may be of particular importance for cells and tissues where FKHRL1 defends against ROS-induced DNA damage by regulating the expression of proteins involved in the repair process (1). The fact that NAC blocked AGE-mediated FKHRL1 phosphorylation further supports the view that AGE-inducible redox changes are early events.
Mitochondrial MnSOD normalizes mitochondrial ROS and also prevents OS-dependent NF-B activation (1, 6 ). In the current study we showed that AGEs can induce a dosedependent decrease in MnSOD protein expression, which appeared by 4 h and persisted for up to 24 h. The effects of AGEs on Akt and FKHRL1 phosphorylation and suppression of MnSOD expression were ameliorated by NAC, as well as by a PI3K inhibitor (LY-294002), indicating that AGE redox effects were also propagated via Akt and FKHRL phosphorylation. Whereas the cause of MnSOD suppression was not fully determined, the mechanisms may include FKHRL1 inactivation due to p66
Shc Ser-36 phosphorylation. These AGE-induced changes were blocked by AGER1 overexpression. This effect was AGER1 specific, based on data showing complete reversal by AGER1 siRNA. Furthermore, the AGE-induced reduction of MnSOD mediated by RAGE was blocked in cells cotransduced with both RAGE and AGER1. This suggests that AGER1 blocks the ROS induced by RAGE and extends our previous finding that AGER1 blocks ROS formation by a RAGE ligand (S-100) (10) . The possible effect of AGER1 on other AGE receptors was not investigated and this could also be informative. In addition, the effects of AGER1 on ROS generated in the mitochondria and/or endoplasmic reticulum remain to be elucidated.
This study points to a new pathway for the induction of OS by two defined AGEs in human kidney cells, which involves downregulation of FKHRL1 activity and MnSOD expression via serine phosphorylation of p66 shc . Since this pathway is blocked by AGER1, the data also identifies a new pathway by which AGER1 defends against OS. Thus the observed decrease of AGER1 found in aging and diabetes (9, 15) may underlie the increased OS and reduced innate antioxidant defenses in these conditions. These data, together with earlier findings, point to a series of phosphorylation events that are linked to AGEinduced stress-responses and that are counteracted by AGER1. Whereas the present studies considered HEK cells, the data may apply to other cell types and tissues where AGER1 regulates stress responses via p66
Shc . AGER1 may thus represent a therapeutic target.
